Mechanisms of innate and acquired resistance to anti-EGFR therapy: a review of current knowledge with a focus on rechallenge therapies

CM Parseghian, S Napolitano, JM Loree… - Clinical Cancer Research, 2019 - AACR
Innate and acquired resistance to anti-EGFR therapy (EGFRi) is a major limitation in the
treatment of metastatic colorectal cancer (mCRC). Although RAS genes are the most …
被引用次数：95 相关文章

Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies.

CM Parseghian, S Napolitano, JM Loree… - … Cancer Research: an …, 2019 - europepmc.org
Innate and acquired resistance to anti-EGFR therapy (EGFRi) is a major limitation in the
treatment of metastatic colorectal cancer (mCRC). Although RAS genes are the most …

Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies

CM Parseghian, S Napolitano, JM Loree… - Clinical Cancer …, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Innate and acquired resistance to anti-EGFR
therapy (EGFRi) is a major limitation in the treatment of metastatic colorectal cancer …

Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies

CM Parseghian, S Napolitano… - … cancer research: an …, 2019 - pubmed.ncbi.nlm.nih.gov
Innate and acquired resistance to anti-EGFR therapy (EGFRi) is a major limitation in the
treatment of metastatic colorectal cancer (mCRC). Although RAS genes are the most …
[HTML] nih.gov

[HTML][HTML] Mechanisms of Innate and Acquired Resistance to anti-EGFR therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies

CM Parseghian, S Napolitano, JM Loree… - … cancer research: an …, 2019 - ncbi.nlm.nih.gov
Innate and acquired resistance to anti-EGFR therapy (EGFRi) is a major limitation in the
treatment of metastatic colorectal cancer (mCRC). Although RAS genes are the most …

Mechanisms of innate and acquired resistance to anti-EGFR therapy: A review of current knowledge with a focus on rechallenge therapies

CM Parseghian, S Napolitano… - Clinical Cancer …, 2019 - mdanderson.elsevierpure.com
Innate and acquired resistance to anti-EGFR therapy (EGFRi) is a major limitation in the
treatment of metastatic colorectal cancer (mCRC). Although RAS genes are the most …

Mechanisms of innate and acquired resistance to anti-EGFR therapy: A review of current knowledge with a focus on rechallenge therapies

CM Parseghian, S Napolitano, JM Loree… - CLINICAL CANCER …, 2019 - iris.unicampania.it
Innate and acquired resistance to anti-EGFR therapy (EGFRi) is a major limitation in the
treatment of metastatic colorectal cancer (mCRC). Although RAS genes are the most …